Navigation Links
Drugs Approved Under Deadline More Likely to Run Into Trouble Later
Date:3/26/2008

e. "For drugs used to treat cardiovascular risk factors, the FDA needs to work with the sponsor, as it wisely did for the approval of torcetrapib, so that large, long-term trials evaluating new drugs that will be used by millions of U.S. individuals start early, evaluate the reduction in cardiovascular disease incidence, and are completed soon after drug approval."

More information

The U.S. Food and Drug Administration has more on PDUFA.



SOURCES: Daniel Carpenter, Ph.D., professor of government, Harvard University, Cambridge, Mass.; Steven Nissen, M.D., chairman, Department of Cardiovascular Medicine, Cleveland Clinic Foundation; March 27, 2008, New England Journal of Medicine; March 26, 2008, Journal of the American Medical Association


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Page: 1 2 3 4

Related medicine news :

1. New review suggests caution on drugs to raise good cholesterol
2. Can cancer drugs combine forces?
3. Study provides hope that some transplant patients could live free of antirejection drugs
4. Study provides hope that some transplant patients could live free of anti-rejection drugs
5. RA Drugs Linked to Slight Skin Cancer Risk
6. Report on patients access to cancer drugs uses flawed methods to reached flawed conclusions
7. Rock N Roll: Sex, Drugs and an Early Exit
8. Australian-led international study shows blood pressure drugs cut death rate in type 2 diabetes
9. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
10. Are Bargaining Groups Hired by Independent Drugstores Causing Payment Delays to Pharmacies?
11. 2 drugs equally effective for heart patients undergoing angioplasty, Mayo study finds
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Drugs Approved Under Deadline More Likely to Run Into Trouble Later
(Date:8/31/2015)... Plains, NJ (PRWEB) , ... August 31, 2015 ... ... practice! Garden State Urology was formed in 2008, the result of a merger ... the principle that by working cooperatively, they could provide more cost-effective and higher ...
(Date:8/31/2015)... NJ (PRWEB) , ... August 31, 2015 , ... NJ Top Docs Presents, Dr. Michael ... and raised in Park Ridge, New Jersey, Dr. Michael Betsy graduated from Don Bosco Prep ... hockey and served as team captain in both sports in his senior year. He ...
(Date:8/31/2015)... ... ... Dr. Stewart Shofner of Shofner Vision Center explains what causes lazy ... eye examination can diagnose amblyopia. According to the National Eye Institute (NEI), ... to 3 out of every 100 children. , Dr. Shofner adds, “unless amblyopia ...
(Date:8/31/2015)... ... August 31, 2015 , ... ... marketing communications company announced today that it has officially launched a new website ... new website and brand refresh are more closely aligned with the company’s strategic ...
(Date:8/31/2015)... ... August 31, 2015 , ... Three Bakers Gluten Free ... retailers with even more relevant and easy-to-find information on their offering of gluten-free breads ... has always been an important way for us to share information about our gluten ...
Breaking Medicine News(10 mins):Health News:NJ Top Docs Presents, Garden State Urology! 2Health News:NJ Top Docs Presents, Dr. Michael Betsy! 2Health News:NJ Top Docs Presents, Dr. Michael Betsy! 3Health News:Renowned Eye Surgeon Dr. Stewart Shofner Shares Information about the Causes of Lazy Eye During Amblyopia Awareness Month 2Health News:Renowned Eye Surgeon Dr. Stewart Shofner Shares Information about the Causes of Lazy Eye During Amblyopia Awareness Month 3Health News:Diablo Publications Launches New Company Website 2Health News:Diablo Publications Launches New Company Website 3Health News:Three Bakers Gluten Free Bakery Announces Launch of New Website 2
... Streamlines Health Records Documentation , ... ... , a leading developer of healthcare software solutions for physician ... leader in enterprise content management and business process automation, to ...
... ALLEGAN, Mich., March 24 Perrigo Company (Nasdaq: ... received final approval from the U.S. Food and Drug ... The product has been determined to be therapeutically equivalent ... is indicated for the topical treatment of acne. Klaron(R) ...
... patients are thought to develop these infections, , , TUESDAY, ... in an antibacterial agent to the dressing around the ... reduce the chances that a potentially deadly infection will ... units (ICUs) usually require insertion of a central venous ...
... Using ANCC Certification Tests for Master,s Degree Competency ... Governors University (WGU), www.wgu.edu , and ... , have agreed to work together on a ... ANCC,s Nurse Executive Certification examination as the exit ...
... pleased to announce the formal partnership of the University ... 10x10 program. Bonnie Westra, PhD, RN, Assistant Professor and Co-Director ... will serve as the Director of the University of ... of Minnesota has adapted its tried and true graduate ...
... fatty acids appear protective against advanced prostate cancer, and ... in the COX-2 gene, according to a report in ... American Association for Cancer Research. , "Previous research has ... of the first studies to show protection against advanced ...
Cached Medicine News:Health News:iMedica and Imagetek Team up to Ease Transition to Paperless Medical Practice 2Health News:iMedica and Imagetek Team up to Ease Transition to Paperless Medical Practice 3Health News:iMedica and Imagetek Team up to Ease Transition to Paperless Medical Practice 4Health News:Perrigo Announces FDA Approval for Sulfacetamide Sodium Topical Suspension USP, 10% (Lotion) 2Health News:Drug-Coated Sponges May Limit Catheter Infections 2Health News:ANCC and WGU to Partner on Use of Nurse Credentialing Exams 2Health News:ANCC and WGU to Partner on Use of Nurse Credentialing Exams 3Health News:New AMIA 10x10 Program Partner -- University of Minnesota School of Nursing 2
(Date:8/31/2015)... PARK, Calif. , Aug. 31, 2015 /PRNewswire/ ... company focused on the emerging field of regenerative ... successfully dosed at Chicago -based ... clinical trial evaluating activity of escalating doses of ... with sensory and motor complete cervical spinal cord ...
(Date:8/31/2015)... Vascular Ltd., together with its subsidiaries (the "Company" ... the "Group"), a global company engaged in the ... for the minimally invasive treatment of vascular disease, ... ("BTK") cohort of patients in the Chocolate® Balloon ... 15, 2015 at the 5th Annual Amputation Prevention ...
(Date:8/31/2015)... , Aug. 31, 2015 Research ... addition of the "Prescription Pain Drugs - ... Marijuana - Global Markets, Competitors and Opportunities: 2015 ... their offering. Pain is defined ... with actual or potential tissue damage. At some ...
Breaking Medicine Technology:Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 4Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 5Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 6Final Results From Below-The-Knee Cohort In Chocolate Registry Presented At The 5th Annual Amputation Prevention Conference 2Final Results From Below-The-Knee Cohort In Chocolate Registry Presented At The 5th Annual Amputation Prevention Conference 3Final Results From Below-The-Knee Cohort In Chocolate Registry Presented At The 5th Annual Amputation Prevention Conference 4Prescription Pain Drugs Including Opioid, Anticonvulsant, Injectable/ Inhaled, Topical/ Transdermal, Medical Marijuana - 2015-2020 Analysis and Forecasts 2Prescription Pain Drugs Including Opioid, Anticonvulsant, Injectable/ Inhaled, Topical/ Transdermal, Medical Marijuana - 2015-2020 Analysis and Forecasts 3
... HARBIN, China , May 18 /PRNewswire-Asia-FirstCall/ -- ... (Nasdaq: CSKI ), a leading fully,integrated pharmaceutical company producing ... today announced record financial results,for the first quarter of 2010. ... Form 10-K for 2009. , , First ...
... HARBIN, China , May 18 ... Board: WKBT) ("Weikang" or the,"Company"), a leading developer, manufacturer ... and other health,and nutritional products in the People,s ... the first quarter of fiscal year 2010 ended on ...
Cached Medicine Technology:China Sky One Medical Announces First Quarter 2010 Results 2China Sky One Medical Announces First Quarter 2010 Results 3China Sky One Medical Announces First Quarter 2010 Results 4China Sky One Medical Announces First Quarter 2010 Results 5China Sky One Medical Announces First Quarter 2010 Results 6China Sky One Medical Announces First Quarter 2010 Results 7China Sky One Medical Announces First Quarter 2010 Results 8China Sky One Medical Announces First Quarter 2010 Results 9China Sky One Medical Announces First Quarter 2010 Results 10China Sky One Medical Announces First Quarter 2010 Results 11China Sky One Medical Announces First Quarter 2010 Results 12China Sky One Medical Announces First Quarter 2010 Results 13China Sky One Medical Announces First Quarter 2010 Results 14Weikang Bio-Technology Reports First Quarter 2010 Financial Results 2Weikang Bio-Technology Reports First Quarter 2010 Financial Results 3Weikang Bio-Technology Reports First Quarter 2010 Financial Results 4Weikang Bio-Technology Reports First Quarter 2010 Financial Results 5Weikang Bio-Technology Reports First Quarter 2010 Financial Results 6Weikang Bio-Technology Reports First Quarter 2010 Financial Results 7Weikang Bio-Technology Reports First Quarter 2010 Financial Results 8Weikang Bio-Technology Reports First Quarter 2010 Financial Results 9Weikang Bio-Technology Reports First Quarter 2010 Financial Results 10Weikang Bio-Technology Reports First Quarter 2010 Financial Results 11
... monitor elevates bedside glucose testing to a ... the quality of central laboratory testing. ... strip technology. Current glucose strips use ... system measures and corrects hematocrit interference as ...
The Tag-It™ Cystic Fibrosis ASR reagents can be used by high complexity CLIA approved laboratories for detection of up to 70 mutations and 6 variants (polymorphisms) in the cystic fibrosis tran...
... BreatheX is a wearable CPAP (Continuous Positive ... sleep apnea. The lightweight BreatheX CPAP device ... with its built-in, rechargeable battery, and is ... no longer need to be "plugged in ...
Paraffin Block Storage System...
Medicine Products: